Clinical Trial Update: A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating JNJ-40411813 as supplementary treatment to an antidepressant in adults with Major Depressive Disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• JNJ-40411813

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED